Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: The '5E' study

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 11, Issue 2, 2011, Pages 205-213

  Arroyo, Rafael ^a   Vila, Carlos ^b   Clissold, Steve ^c  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b Almirall ^*  (Spain)

^c Content Ed Net ^*  (Spain)

Author keywords

healthcare costs; multiple sclerosis; Spain; spasticity

Indexed keywords

BACLOFEN; BENZODIAZEPINE DERIVATIVE; BETA1A INTERFERON; BOTULINUM TOXIN; CANNABIS; CLONIDINE; CORTICOSTEROID; DANTROLENE; GABAPENTIN; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; TIZANIDINE;

ADULT; AGED; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HEALTH CARE COST; HEALTH CARE FACILITY; HEALTH CARE SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; PHYSIOTHERAPY; RETROSPECTIVE STUDY; REVIEW; SOCIAL SUPPORT; SPAIN; SPASTICITY;

ADULT; AGED; COST OF ILLNESS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; RETROSPECTIVE STUDIES;

EID: 79953881245     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.11.6     Document Type: Review

References (24)

1. Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 10, 589-595 (2004). (Pubitemid 39207235)
2. Haselkorn JK, Balsdon RC, Fry WD, Herndon RM, Johnson B, Little JW; Multiple Sclerosis Council for Clinical Practice Guidelines. Overview of spasticity management in multiple sclerosis. Evidence-based management strategies for spasticity treatment in multiple sclerosis. J. Spinal Cord Med. 28(2), 167-199 (2005).
3. Bohannon RW, Smith MB. Inter-rater reliability of a modifed Ashworth scale of muscle spasticity Phys. Ther. 67, 206-207 (1987). (Pubitemid 17026064)
4. Farrar JT, Troxel AB, Stott CG, Duncombe P. The validity, reliability, and clinical importance of changes in spasticity severity measured on a 0-10 Numerical Rating Scale. J. Neurol. 254(Suppl. 3), 21 (2007).
5. Farrar JT, Troxel AB, Stott C, Duncombe P, Jensen MP. Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc ana lysis of a randomized, double-blind, placebo-controlled trial. Clin. Ther. 30(5), 974-985 (2008). (Pubitemid 351799873)
6. Penn RD, Savoy SM, Corcos D et al. Intrathecal baclofen for severe spinal spasticity N Engl. J. Med. 320(23), 1517-1521 (1989). (Pubitemid 19145803)
7. Hobart JC, Riazi A, Thompson AJ et al. Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). Brain 129, 224-234 (2006). (Pubitemid 43063773)
8. Bavikatte G, Gaber T Approach to spasticity in general practice. Br. J. Med. Pract 2, 29-34 (2009).
9. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Sys. Rev. 4, CD001332 (2003).
10. Zwibel HL. Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. Adv. Ther. 26(12), 1043-1057 (2009).
11. Sharac J, McCrone P, Sabes-Figuera R. Pharmacoeconomic considerations in the treatment of multiple sclerosis. Drugs 70(13), 1677-1691 (2010).
12. Kobelt G, Berg J, Lindgren P, Fredrikson S, Jönsson B. Costs and quality of life of patients with multiple sclerosis in Europe. J. Neurol. Neurosurg Psychiatry 77, 918-926 (2006). (Pubitemid 44174075)
13. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33, 1444-1451 (1983).
14. Anwar K, Barnes MP. A pilot study of a comparison between a patient scored numeric rating scale and clinician scored measures of spasticity in multiple sclerosis. Neurorehabilitation 24, 333-340 (2009).
15. Ansari NN, Naghdi S, Arab TK, Jalaie S. The interrater and intrarater reliability of the modifed Ashworth scale in the assessment of muscle spasticity: limb and muscle group effect. Neurorehabilitation 23, 231-237 (2008). (Pubitemid 352039968)
16. Hauser SL, Dawson DM, Lehrich JR et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high dose intravenous cyclophosphamide, plasma exchange, and ACTH. N. Engl. J. Med. 308, 173-180 (1983). (Pubitemid 13171135)
17. Snow BJ, Tsui JK, Bhatt MH, Varelas M, Hashimoto SA, Calne DB. Treatment of spasticity with botulinum toxin: a double-blind study. Ann. Neurol. 28, 512-515 (1990). (Pubitemid 20359157)
18. Anon. Aids to the investigation of peripheral nerve injury. War Memorandum Number 45. HMSO, London, UK (1976)
19. Buhse M. Assessment of caregiver burden in families of persons with multiple sclerosis. J. Neurosci. Nurs. 40, 25-31 (2008).
20. Stevenson VL. Rehabilitation in practice: spasticity management. Clin. Rehabil. 24, 293-304 (2010).
21. Fleuren JF, Voerman GE, Erren-Wolters CV et al. Stop using the Ashworth Scale for the assessment of spasticity. J. Neurol. Neurosurg Psychiatry 81, 46-52 (2010).
22. Casado V, Romero L, Gubieras L et al. An approach to estimating the intangible costs of multiple sclerosis according to disability in Catalonia, Spain. Mult Scler. 13(6), 800-804 (2007). (Pubitemid 47074105)
23. 2, cannabinoid receptors. Br. J. Pharmacol. 150, 19-25 (2007).
24. House H, Bateman C, Wade DT Long-term Sativex (THC:CBD) use in multiple sclerosis: benefts to daily life and functional activities. Mult Scler. 13, S267 (2007).